Posted by Michael Wonder on 16 Feb 2022
GE Healthcare's stress agent Rapiscan approved for use in stress cardiac magnetic resonance imaging
14 February 2022 - Already used in single photon emission computed tomography (SPECT) myocardial perfusion imaging for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging.
GE Healthcare has announced that it has received approval from the EMA for additional imaging modalities for its stress agent Rapiscan (Regadenoson).
